Laurini Erik, Marson Domenico, Aulic Suzana, Fermeglia Maurizio, Pricl Sabrina
Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), Department of Engineering and Architecture, University of Trieste, 34127 Trieste, Italy.
Pharmaceutics. 2019 Jul 10;11(7):324. doi: 10.3390/pharmaceutics11070324.
In part I of this review, the authors showed how poly(amidoamine) (PAMAM)-based dendrimers can be considered as promising delivering platforms for siRNA therapeutics. This is by virtue of their precise and unique multivalent molecular architecture, characterized by uniform branching units and a plethora of surface groups amenable to effective siRNA binding and delivery to e.g., cancer cells. However, the successful clinical translation of dendrimer-based nanovectors requires considerable amounts of good manufacturing practice (GMP) compounds in order to conform to the guidelines recommended by the relevant authorizing agencies. Large-scale GMP-standard high-generation dendrimer production is technically very challenging. Therefore, in this second part of the review, the authors present the development of PAMAM-based amphiphilic dendrons, that are able to auto-organize themselves into nanosized micelles which ultimately outperform their covalent dendrimer counterparts in in vitro and in vivo gene silencing.
在本综述的第一部分,作者展示了基于聚(酰胺胺)(PAMAM)的树枝状大分子如何被视为用于siRNA治疗的有前景的递送平台。这得益于其精确且独特的多价分子结构,其特征在于均匀的分支单元和大量适合有效结合siRNA并递送至例如癌细胞的表面基团。然而,基于树枝状大分子的纳米载体的成功临床转化需要大量符合良好生产规范(GMP)的化合物,以符合相关授权机构推荐的指导方针。大规模生产符合GMP标准的高代树枝状大分子在技术上极具挑战性。因此,在本综述的第二部分,作者介绍了基于PAMAM的两亲性树枝状分子的开发,它们能够自组装成纳米尺寸的胶束,最终在体外和体内基因沉默方面优于其共价树枝状大分子对应物。